Natale Cascinelli

Q: What Schools Are Affiliated With Natale Cascinelli

Natale Cascinelli is affiliated with the following schools: University of Milan, University of Sydney, University of Birmingham

Natale Cascinelli's AcademicInfluence.com Rankings

Natale Cascinelli

Medical

#3156

World Rank

#3611

Historical Rank

Oncology

#217

World Rank

#225

Historical Rank

Surgery

#262

World Rank

#321

Historical Rank

medical Degrees

Natale Cascinelli

Philosophy

#9091

World Rank

#12596

Historical Rank

Logic

#6083

World Rank

#7565

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Natale Cascinelli's Degrees

Doctorate Medicine University of Milan
PhD Oncology University of Milan

Why Is Natale Cascinelli Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Natale Cascinelli's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. (2002) (3814)
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. (2001) (2651)
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. (2001) (2315)
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma (1996) (1121)
Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial (1998) (625)
Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. (1977) (607)
Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. (1991) (465)
Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma (1992) (435)
A new American Joint Committee on Cancer staging system for cutaneous melanoma (2000) (428)
NIH Consensus conference. Diagnosis and treatment of early melanoma. (1992) (420)
An Evidence‐based Staging System for Cutaneous Melanoma 1 (2004) (420)
Thin Stage I Primary Cutaneous Malignant Melanoma (1988) (419)
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. (2010) (389)
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. (2002) (387)
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities (1982) (379)
Prognosis of Breast Cancer Patients after Mastectomy and Dissection of Internal Mammary Nodes (1985) (348)
Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. (1996) (334)
Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience (2000) (328)
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. (2011) (327)
Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors (1991) (278)
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial (2001) (236)
Risk of Internal Mammary Lymph Node Metastases and Its Relevance on Prognosis of Breast Cancer Patients (1983) (200)
Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. (1988) (194)
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. (2003) (193)
Lack of effect of pregnancy on outcome of melanoma (1991) (188)
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. (2000) (185)
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. (2001) (166)
Stage I melanoma of the skin: Evaluation of prognosis according to histologic characteristics (1981) (163)
Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments. (1985) (163)
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. (2001) (157)
Results of adjuvant interferon study In WHO melanoma programme (1994) (154)
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma (1982) (151)
Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. (2000) (150)
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. (1991) (144)
Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. (1993) (143)
Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials (2007) (138)
Cellular and humoral immunity against human malignant melanoma (1971) (137)
Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. (2006) (136)
A possible new tool for clinical diagnosis of melanoma: the computer. (1987) (133)
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. (2003) (128)
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. (1997) (127)
Results obtained by using a computerized image analysis system designed as an aid to diagnosis of cutaneous melanoma (1992) (112)
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. (1982) (110)
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. (2006) (106)
Regional non-nodal metastases of cutaneous melanoma. (1986) (102)
In vivo SPECTROPHOTOMETRIC EVALUATION OF NEOPLASTIC AND NON‐NEOPLASTIC SKIN PIGMENTED LESIONS–I. REFLECTANCE MEASUREMENTS (1991) (91)
Stage I Melanoma of the Limbs: Assessment of Prognosis by Levels of Invasion and Maximum Thickness (1978) (91)
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. (1996) (87)
Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination (2004) (87)
HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. (2002) (86)
In vivo SPECTROPHOTOMETRIC EVALUATION OF NEOPLASTIC AND NON‐NEOPLASTIC SKIN PIGMENTED LESIONS. II: DISCRIMINANT ANALYSIS BETWEEN NEVUS AND MELANOMA (1992) (82)
Treatment of primary or relapsing limb cancer by isolation perfusion with high‐dose alpha‐tumor necrosis factor, gamma‐interferon, and melphalan (1994) (76)
Prognosis of skin melanoma with regional node metastases (stage II) (1984) (74)
Neurotoxicity of interferon‐α in melanoma therapy (1998) (72)
National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27–29, 1992 (1993) (70)
Multiple Primary Melanoma (1975) (69)
Margin of resection in the management of primary melanoma (1998) (68)
Stage I Melanoma of the Limbs. Immediate versus Delayed Node Dissection (1980) (67)
Prognosis of breast cancer with axillary node metastases after surgical treatment only. (1987) (64)
Evaluation of efficacy of adjuvant rIFN-alfa-2a in melanoma patients with regional nodal metastases (abstract) (1995) (64)
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. (1999) (62)
Bans: A cutaneous region with no prognostic significance in patients with melanoma (1986) (61)
Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. (1993) (60)
Sentinel-node biopsy in melanoma. (2006) (60)
Acral lentiginous melanoma. A histological type without prognostic significance. (1994) (55)
Prognosis based on primary breast carcinoma instead of pathological nodal status. (1994) (55)
Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities (1989) (54)
Small melanomas: a clinical study on 270 consecutive cases of cutaneous melanoma. (1999) (49)
In vivo SPECTROPHOTOMETRIC EVALUATION OF NEOPLASTIC AND NONNEOPLASTIC SKIN PIGMENTED LESIONS. III. CCD CAMERA‐BASED REFLECTANCE IMAGING (1995) (48)
Optical imaging and automated melanoma detection: questions and answers (2002) (47)
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (47)
Immunoscintigraphy with 123I, 99mTc and 111In-labelled F(ab')2 fragments of monoclonal antibodies to a human high molecular weight-melanoma associated antigen. (1984) (44)
Evaluation of the Risk of Multiple Primaries in Malignant Cutaneous Melanoma (1976) (44)
The invisible colours of melanoma. A telespectrophotometric diagnostic approach on pigmented skin lesions. (1996) (44)
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. (1994) (44)
Spectrophotometric imaging of cutaneous pigmented lesions: discriminant analysis, optical properties and histological characteristics. (1998) (43)
Excision of primary melanoma (1993) (43)
Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities. (1987) (42)
The New Melanoma Staging System (2001) (41)
Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). (1994) (39)
In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2 (1988) (39)
S100 protein serum levels in cutaneous malignant melanoma. (1998) (37)
Prognostic factors for stage I melanoma of the skin: a review. (1985) (37)
Micro-Melanoma Detection. A Clinical Study on 22 Cases of Melanoma with a Diameter Equal to or Less than 3 MM (2004) (37)
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors (1999) (36)
Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. (1999) (36)
Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer. (1999) (35)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). (1989) (33)
Margin of resection in the management of primary melanoma. (1998) (33)
Thyroid Cancer in Childhood (1978) (32)
Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. (1994) (31)
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. (1976) (31)
Preliminary clinical studies with PDT by topical TPPS administration in neoplastic skin lesions (1987) (31)
Preoperative approach to thyroid tumours by a two-dimensional pulsed echo technique. (1968) (30)
Do patients with tumor-positive sentinel nodes constitute a homogeneous group? (2001) (30)
Metastatic Spread of Stage I Melanoma of the Skin (1983) (30)
Melanoma Detection (2002) (29)
Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients. (1999) (27)
Phase II Study of Interferon α‐2a and Dacarbazine in Advanced Melanoma (1990) (26)
The role of parotidectomy in the treatment of nodal metastases from cutaneous melanoma of the head and neck. (1990) (26)
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (24)
Clinical diagnosis and therapy of cutaneous melanoma in situ (1996) (24)
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. (2003) (23)
Prognostic Factors in Operable Breast Cancer (1983) (23)
Regional Perfusion at High Temperature in Treatment of Stage IIIA-IIIAB Melanoma Patients (1983) (23)
HLA complex and familial malignant melanoma (1982) (23)
Hemostatic alterations are unrelated to the stage of tumor in untreated malignant melanoma and breast carcinoma. (1985) (22)
No additive impact on patient survival of the double alteration of p53 and c-erbB-2 in breast carcinomas. (1996) (22)
The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients (2004) (21)
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung (2004) (21)
Ambulatory narrow excision for thin melanoma (< or = 2 mm): results of a prospective study. (1997) (20)
New trends in the treatment of malignant melanoma. (1978) (20)
Cytokine-based gene therapy of human tumors. An overview. (1996) (19)
A reappraisal of oophorectomy in carcinoma of the breast. (1987) (19)
Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients (1998) (19)
Hyperthermic antiblastic perfusion in extracorporeal circulation: surgical technique and results in the treatment of extremities tumor (1986) (18)
Prognosis of malignant melanoma according to regional metastases. (1971) (18)
Cancer Prevalence. What for? (1999) (18)
Sentinel Node Biopsy and Selective Dissection for Melanoma Nodal Metastases (1998) (18)
Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. (1998) (18)
World Health Organization experience in the treatment of melanoma. (2003) (17)
Association between Cutaneous Melanoma and Neurofibromatosis Type 1: Analysis of Three Clinical Cases and Review of the Literature (2000) (17)
What is the most promising strategy for the treatment of metastasizing melanoma? (2000) (17)
Locally recurrent breast cancer after 'radical' surgery. (1992) (17)
CO2 lasers: Beam patterns in relation to surgical use (1983) (17)
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2 (1993) (16)
Controlled Study with Imidazole Carboxamide (DTIC), DTIC + Bacillus Calmette-Guérin (BCG), and DTIC + Corynebacterium Parvum in Advanced Malignant Melanoma (1984) (16)
Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas (1995) (16)
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). (1999) (15)
Malignant Melanoma of the Vulva (1970) (15)
Elective lymph node dissection for melanoma: Two perspectives (1992) (15)
Sentinel Node Biopsy in Patients with Cutaneous Melanoma of the Head and Neck (2000) (15)
Changes in fibrinolysis in patients with localized tumors. (1990) (13)
Impact of clinical trials on the treatment of melanoma. (2001) (13)
Long Term Results of Surgical Treatment of Melanoma of the Limbs (1976) (12)
Role of surgery in treatment of advanced differentiated thyroid carcinomas. (2007) (12)
Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells. (1998) (12)
Malignant Malanoma of the Penis (1969) (12)
Comparison of long‐term survival of 1986 consecutive patients with breast cancer treated at the national cancer institute of milano, italy (1971 to 1972 and 1977 to 1978) (1991) (12)
Cutaneous melanoma : status of knowledge and future perspective (1987) (11)
Surgical Treatment of Gastric Metastases from Cutaneous Melanoma: Experience of the National Cancer Institute of Milan (2001) (11)
Let's stop worrying about pigmented skin lesions in children. (1994) (11)
Childhood Cutaneous Melanoma (1994) (11)
Long-Term Survival and Prognostic Factors for 2170 Breast Cancer Patients Treated at Two Cancer Centers: (Milan and Houston) (1989) (11)
A Multiparametric Study by Monoclonal Antibodies in Breast Cancer (1987) (11)
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin‐2 and lymphokine activated killer cells. A pilot study (1992) (10)
A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma (2001) (10)
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation. (1989) (10)
Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients (1996) (10)
Second thoughts on the value of selective thyroid angiography. (1972) (10)
Cell kinetics: an independent prognostic variable in stage II melanoma of the skin. (1990) (9)
Radioimmunodetection of Malignant Melanoma with Radiolabelled (131I, 123I, 111In, 99mTc) Monoclonal Antibodies and F(ab′)2 Fragments (1986) (9)
Lymphocyte toxicity test in clinical melanoma. (1973) (8)
Methods and impact of controlled therapeutic trials in cancer (1978) (8)
Evaluation of Toxic Effects following Administration of Monoclonal Antibody MBr1 in Patients with Breast Cancer (1986) (8)
Telespectrophotometry of human skin diseases by means of a CCD camera (1994) (8)
Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma (1993) (8)
Intravenous Administration of BCG in Advanced Melanoma Patients (1978) (7)
Cancer epidemiology, environmental factors (1975) (7)
Laser oncology in Italy: experimental research and clinical applications at the National Cancer Institute, Milan (1983) (7)
Limb salvage in osteogenic sarcoma of extremities: a new therapeutic approach associating infusion and hyperthermic antiblastic perfusion (1987) (7)
Treatment of regional nodes. (1992) (7)
Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells (2004) (7)
The editorialists reply [11] (2007) (6)
Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies (1986) (6)
The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes. (1996) (6)
Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma (1995) (6)
Breast Cancer: Primary Tumor Characteristics Related to Lymph Node Involvement (1981) (5)
[PAPILLIFEROUS CARCINOMA APPEARING ON A CYST OF THE THYROGLOSSAL DUCT]. (1964) (5)
Present status and future perspectives of adjuvant treatment of cutaneous malignant melanoma (1983) (5)
Combined effects of interferon-α2a and 13-cisretinoic acid on human melanoma cell growth and STAT protein expression (1998) (5)
[Solitary plasmocytoma of the thyroid gland]. (1966) (5)
Melanoma of the Skin (1989) (5)
Melanoma and pregnancy (1991) (5)
Solitary Plasmocytoma of the Thyroid (1966) (5)
Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients. (1997) (4)
Surgical treatment of malignant melanoma of the skin (1979) (4)
Adjuvant interferon in melanoma (1994) (4)
A new Procedure for Large Scale Production and Freezing of Lymphokine Activated Killer (LAK) Cells to be used in Adoptive Immunotherapy of Cancer (1988) (4)
Prognosis of Melanoma of the Vulva. (1975) (4)
Papillary Carcinoma of the Thyroglossal Duct (1964) (4)
Distant Metastases from Thyroid Carcinomas (1967) (4)
Margins of of resection of malignant melanomas that are less than the hitherto conventional "wide and deep" margins are not advisable as yet. (1985) (4)
Study of the biological and prognostic significance of the antigen CaMBr8 on breast carcinoma. (1992) (4)
Reflectance imaging spectroscopy: possible aid in the clinical diagnosis of melanoma (1995) (4)
Breast carcinoma in young patients (2000) (4)
Monoclonal antibodies as prognostic indicators of tumor progression in breast cancer. (1988) (4)
Study of Sunbathing in Children: The Preliminary Evaluation of a Prevention Program (2005) (4)
Intranodular Treatment with BCG of Cutaneous and Subcutaneous Metastases of Malignant Melanoma. (1974) (4)
Pituitary ablation with 90Y implant in advanced thyroid cancer (1967) (3)
PHENOTYPIC HETEROGENEITY OF HLA PRODUCTS ON HUMAN MELANOMA CELLS (1986) (3)
HLA Antigens in Familial and Sporadic Cutaneous Melanoma (1988) (3)
Prognostic Factors in Malignant Melanoma (1966) (3)
The case for minimal margins and delayed regional node dissection for high-risk cutaneous melanoma. (1993) (3)
Outpatient surgical treatment of cutaneous melanoma (1992) (3)
Cervical Metastases as First Symptom of Thyroid Cancer (1964) (3)
Long Term Results of Randomized Trial Comparing Immediate Versus Delayed Node Dissection in Stage I Melanoma of the Limbs (1984) (3)
[CARCINOMA AND SARCOMA APPEARING IN RADIODERMITIS]. (1964) (3)
[Impact of sentinel lymph node biopsy on the treatment of melanoma]. (2003) (3)
Excision of primary melanoma should allow primary closure of the wound. (1995) (3)
Evaluation on serum 2'-5'oligoadenylate synthetase (2'-5'oligoAS) and beta 2 microglobulin (B2M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A. (1998) (3)
Monoclonal Antibodies MBr1 and MBr8 as Predictors of Response to Oophorectomy in Advanced Breast Cancer (1988) (2)
Dissection of regional lymph nodes in cutaneous melanoma (1998) (2)
Unusual association between cutaneous melanoma and axillary metastasis from occult breast cancer detected by sentinel node biopsy. (2000) (2)
Resection margins for stage I cutaneous melanoma. (1994) (2)
Results of WHO melanoma programme international study on computerized image analysis: 19 (1993) (2)
Response: lymph node dissection for stage I melanoma: the unresolved dilemma. (1982) (2)
Predicting potential of c-erbB-2 orcoprotein and laminin receptor expression on primary breast cancer (1993) (2)
[Considerations on the usefulness of transcutaneous biopsy in the diagnosis of bone diseases]. (1965) (2)
Clinical status of diagnosis and therapy of malignant melanoma. (1989) (2)
131-I accumulation in a cystoadenoma lymphomatosum of the parotid gland. (1967) (2)
Alpha melanocyte stimulating hormone in human melanoma (1987) (2)
Combined treatment of osteosarcoma of the limbs at an advanced stage, including hyperthermic-antiblastic perfusion. (1990) (2)
Intralymphatic administration of BCG in melanoma patients (1977) (2)
Identification of HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviours (2001) (2)
Surgery, radiotherapy and chemotherapy of cancer (1975) (2)
A Case of Multiple Granular Cell Myoblastoma of the Tongue. (1966) (2)
New prospects for melanoma research. (1973) (2)
Cell biology and tumor immunology (1975) (2)
[6 cases of thyroid carcinoma in childhood]. (1963) (2)
Monomorphic cellular proliferation of malignant melanomas of the skin as a prognostic morphologic parameter. (1980) (2)
Long term results of surgical treatment of thyroid cancer. (1977) (2)
24 The WHO low dose adjuvant Interferon study: an update (1997) (2)
Proceedings of the eleventh international cancer congress. Volume III. Cancer epidemiology, environmentals factors. Conference held at Florence, Italy, October 20--26, 1974 (1975) (2)
[Scintigraphy in the diagnosis of the nature of thyroid nodules]. (1966) (1)
Surgical treatment of cutaneous melanoma (1990) (1)
Solitary Melanoma Metastasis of the Kidney: A Case Report (1996) (1)
CLINICAL DIAGNOSIS AND THERAPY OF CUTANEOUS MELANOMA IN SITU. AUTHORS' REPLY (1996) (1)
Excision Margins for Primary Cutaneous Melanoma—Invited Critique (2007) (1)
In Situ and Very thin Melanomas (< 0.75 mm) are Similarly and Commonly Recognizable (1996) (1)
Regional perfusion in the treatment of locally advanced pelvic cancer (1994) (1)
Prognostic F actors A nalysis o f 1 7,600 M elanoma P atients: Validation o f t he A merican J oint C ommittee o n C ancer Melanoma S taging S ystem (2001) (1)
Comments on primary and adjuvant treatments of breast cancer. (1988) (1)
Melanoma of the vulva a clinicopathologic study on 28 cases (1986) (1)
[Mesenchymal malignant tumors of the thyroid]. (1969) (1)
Advances in computer-assisted diagnosis of melanoma: the telespectrophotometric approach (1997) (1)
Specific Immunogenicity of Human Breast Carcinoma Extracts in Rabbits (1972) (1)
11 Recent developments of immunotherapy in melanoma patients.The experience of Milano National Cancer Institute (1997) (1)
Re: Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. (1995) (1)
A Case of Adenolymphoma in the Thyroid Gland (1964) (1)
Proceedings XI International Cancer Congress, Florence 1974. Vol. IV: Cancer campaign, detection, rehabilitation, clinical classification (1975) (1)
Melanoma Today (1988) (1)
Clinical approaches: 4 (1993) (1)
Imaging techniques for computer-assisted diagnosis of skin-pigmented lesions (1996) (1)
Malignant Mesenchymal Tumors of the Thyroid (1969) (1)
Adoptive Immunotherapy of Melanoma with Interleukin-2 and Lymphocytes (1993) (1)
COMMENT ON : PREDICTION OF AXILLARY LYMPH NODE STATUS IN BREAST CANCER PATIENTS BY USE OF PROGNOSTIC INDICATORS. AUTHORS' REPLY (1995) (0)
New therapeutic strategies for rectal melanoma: Total rectal resection with coloendoanal anastomosis (1998) (0)
Author reply (0)
Scanning in the Preoperative Diagnosis of Thyroid Nodules (1966) (0)
[Hidden foci of carcinoma in thyroid adenomas]. (1966) (0)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
Treatment of stage IV melanoma patients with interleukin-2 (IL-2) and autologous tumor infiltrating lymphocytes (TIL): 291 (1993) (0)
Erratum: Elective lymph node dissection for melanoma: Two perspectives (World Journal of Surgery (1992) 16 (203-212)) (1993) (0)
[Sun light (not only UV light), melanoma, skin tumors ... and ethics]. (1989) (0)
Response: Lymph node dissection for stage i melanoma: the unresolved dilemma (1982) (0)
Proceedings of the eleventh international cancer congress. Volume I. Cell biology and tumor immunology. Conference held at Florance, Italy, October 20--26, 1974 (1975) (0)
Stem Cells Research: Impact on Molecular Biology of Cancer and Prospects for Therapy of Neoplastic Diseases (2000) (0)
[Immunological aspects in the treatment of malignant melanoma]. (1982) (0)
INV 11 Sentinel node biopsy: a mini-invasive procedure to plan surgical treatment of stage IB and II melanoma patients (2007) (0)
A Case of Carcinoma and Sarcoma in Radiation Dermatitis (1964) (0)
Contents Vol. 205, 2002 (2002) (0)
Differences between in Vivoand in Vitro Activation of Cancer Patient Lymphocytes by Recombinant Inter leukin 2 : Possible Role for Lymphokine-activated Killer Cell Infusion in the in F / vo-induccd Activation 1 (2006) (0)
Narrower Surgical Margins Might be Sufficient in Invasive Horizontal Growth Phase Melanoma (2004) (0)
Malignant: Results of surgical treatment of malignant melanoma localized in the limbs. (Italian) (1978) (0)
519 Treatment of peritoneal carcinosis using hyperthermic intraperitoneal perfusion (1995) (0)
Surgical pros and cons. The debate over immediate lymph node dissection in melanoma. (1979) (0)
Proceedings XI International Cancer Congress, Florence 1974. Vol. II: Chemical and viral oncogenesis (1975) (0)
997 Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study (1995) (0)
[Primary malignant lymphogranuloma of the thyroid gland]. (1966) (0)
Abstracts reprinted from journal of clinical oncology (2007) (0)
Regional Lymph Node Metastases in the Prognosis of Melanoma (1969) (0)
Acknowledgement to Referees for Dermatology 2002 (2002) (0)
The Role of Interferon in the Adjuvant Treatment of Cutaneous Melanoma (1999) (0)
Cutaneous melanoma is less frightening if treated in outpatient regime (1993) (0)
Proceedings XI International Cancer Congress, Florence 1974. Vol. III: Cancer epidemiology, environmental factors (1975) (0)
Occult Carcinoma in Thyroid Adenoma (1966) (0)
The Transcutaneous Biopsy in the Diagnosis of Bone Affections. (1965) (0)
Active Immunotherapy in Melanoma Patients: New Experiences at National Cancer Institute of Milan (1997) (0)
Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes. (1988) (0)
216 Isolated limb perfusion for stage IIIA-IIIAB melanoma: TNF + L-PAM and L-PAM + hyperthermia (1995) (0)
5 Interferon in the adjuvant setting of melanoma: reality or mirage? (1999) (0)
3 Regional lymph node metastases from malignant melanoma: prognostic factors influencing survival (1997) (0)
Systemic therapy of melanoma (1994) (0)
753 Isolated pelvic perfusion for treatment of non-resectable pelvic recurrences (1995) (0)
ADJUVANT INTERFERON IN MELANOMA. AUTHOR'S REPLY (1994) (0)
[Sex and age in the diagnosis of the nature of thyroid nodules]. (1969) (0)
[Radiological aspects of synovial sarcoma. Analysis of 41 cases]. (1969) (0)
Active immunization of metastatic melanoma patients with IL-2 gene-transferred, allogeneic melanoma cells (1996) (0)
Primary Hodgkin's Disease of the Thyroid (1966) (0)
Surgical management of primary melanoma: excision biopsy and wide local excision (2003) (0)
[Ultraviolet rays and skin melanoma]. (1988) (0)
V a c c ination o f M etastatic M elanoma P atients W ith Autologous T umor-Derived H eat S hock P rotein g p96- Peptide C omplexes: C linical a nd I mmunologic F indings (2002) (0)
Surgical Research in Italy (1991) (0)
Elective regional lymph node dissection for melanoma (2003) (0)
220b Intravenous high dose thymopentin in metastatic melanoma patients: Evaluation of toxicity and clinical efficacy (1995) (0)
Cancer campaigns, detection, rehabilitation, clinical classification (1975) (0)
Inconsistent expression of HLA-B antigens on peripheral blood lymphocytes of stage I melanoma patients: an indicator of poor prognosis. (1994) (0)
Clinical Applications of Molecular Oncology (1996) (0)
[Epidemiology, etiological factors and histological classification of malignant tumors of the thyroid]. (1971) (0)
Proceedings XI International Cancer Congress, Florence 1974. Vol. V: Surgery, Radiotherapy and Chemotherapy of Cancer (1975) (0)
Subject Index Vol. 205, 2002 (2002) (0)
Surgical treatment of melanoma of the trunk (1985) (0)
Long term results on acral lentiginous melanoma: our experience from 1975 to 1990 (1993) (0)
[CERVICAL METASTASES AS THE FIRST SIGN OF THYROID CARCINOMA]. (1964) (0)
TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomas (phase I-II study): Preliminary results (1996) (0)
Cutaneous melanoma is less frightening if treated in an outpatient regime: 385 (1993) (0)
Thyroid Carcinoma in Childhood: Report of Six Cases (1963) (0)
[Therapeutic planning and prognosis in cutaneous malignant melanoma]. (1969) (0)
[Therapeutic and prognosis of malignant tumors of the thyroid]. (1970) (0)
Childhood cutaneous melanoma: 149 (1993) (0)
[The monthly bibliographic selection: prophylactic adenectomy of a melanoma sentinel node]. (1999) (0)
Dohi memorial lecture. Melanoma today. (1988) (0)
Pre operative approach to thyroid tumors by a 2 dimensional pulsed echo technique (1968) (0)
1275 Preliminary clinical results of active immunization with interleukin-4 gene transfected allogeneic melanoma cells in metastatic melanoma patients (1995) (0)
Management of primary cutaneous melanoma of head and neck: 384 (1993) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Natale Cascinelli?

Natale Cascinelli is affiliated with the following schools:

Natale Cascinelli's Academic­Influence.com Rankings

Natale Cascinelli's Degrees

Why Is Natale Cascinelli Influential?

Natale Cascinelli's Published Works

Published Works

What Schools Are Affiliated With Natale Cascinelli?

Natale Cascinelli's AcademicInfluence.com Rankings